SCHEMBL377231

SCHEMBL377231

CC(C)c1oc(-c2ccccc2Cl)nc1CI

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.44
TP53 P04637 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HPGD P15428 2/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
C1R P00736 1/20 0.40
NOTUM Q6P988 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ELANE P08246 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5846121 0.89 PPARG (0.48) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL5845568 0.83 PPARG (0.51) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL5845282 0.83 KDM4E (0.50) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL376946 0.83 PPARG (0.48) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL5846647 0.81 PPARD (0.52) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL28757708 0.81 HSD17B10 (0.45) PPARGPPARDSMN1; SMN2TP53NPC1
SCHEMBL5845152 0.77 PPARD (0.45) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL5845148 0.77 PPARD (0.45) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL376647 0.76 PPARG (0.42) PPARGPPARDPPARASMN1; SMN2TP53
SCHEMBL376646 0.76 PPARG (0.42) PPARGPPARDPPARASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-7078422-B2 Activator for peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2006-07-18 US disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040152744-A1 Activator for peroxisome proliferator- activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2004-08-05 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1371650-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR NIPPON CHEMIPHAR CO., LTD. (JP) 2003-12-17 EP disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152744-A1 Activator for peroxisome proliferator- activated receptor PPARA, PPARG, PPARD PPARG 2/4885PPARD 3/4885PPARA 1/4885
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARG 2/4885PPARD 1/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.